Phase 3 Data Backs Novartis' Afinitor

Data published in the medical journal The Lancet showed a significant reduction of kidney tumors due to tuberous sclerosis complex (TSC) in patients enrolled in a phase 3 trial of Novartis' (NYSE: NVS  ) drug Afinitor, the company announced in a press statement released Thursday.

TSC, a rare disease that Novartis says affects between 1 million and 2 million people across the globe, is a genetic disorder that can cause non-malignant tumors to grow in various parts of the body, including the kidneys. The EXIST-2 phase 3 trial for Afinitor showed a response rate of 42% of patients taking the drug, compared to 0% taking a placebo.

The findings are one more piece of data to support Afinitor, which has already received regulatory approval to treat these tumors in both the United States and European Union.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2191646, ~/Articles/ArticleHandler.aspx, 4/21/2014 8:12:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement